Glenmark Pharmaceuticals (NSE:GLENMARK) Total Equity: ₹105,118 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
88 GF Score
Price ₹2,286.90
GF Value ₹1,986.35
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals Total Equity?

Glenmark Pharmaceuticals NSE:GLENMARK -0.46% 88 Total Equity is ₹105,118 Mil as of Mar. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 88/100 and a GF Value™ of ₹1,986.35 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Glenmark Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was ₹105,118 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Glenmark Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Total Equity Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94,381.20 98,392.59 78,475.47 88,490.70 105,117.93

Glenmark Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88,490.70 0.00 95,816.28 0.00 105,117.93
NSE:GLENMARK
88GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Glenmark Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=199078.76-93960.83
=105,118

Glenmark Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=199078.76-93960.83
=105,118

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹105,118 Mil mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Total Equity of ₹105,118 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Total Equity too high?
Glenmark Pharmaceuticals' current Total Equity is ₹105,118 Mil. Overall, Glenmark Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Total Equity compare to ZTS and UTHR?
Glenmark Pharmaceuticals' Total Equity of ₹105,118 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Total Equity is ₹105,118 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,986.35, compared to a current price of ₹2,286.90 — trading 15.1% above its estimated fair value. The current Total Equity is ₹105,118 Mil. Glenmark Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Total Equity is ₹105,118 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,286.90 is trading 15.1% above its estimated GF Value™ of ₹1,986.35. GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:GLENMARK:

  • Total Equity: ₹105,118 Mil
  • GF Value™: ₹1,986.35 vs. price of ₹2,286.90 (15.1% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score

Get the complete analysis for NSE:GLENMARK

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,286.90
Price
₹1,986.35
GF Value